HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Faculty of Pharmaceutical Sciences >
Peer-reviewed Journal Articles, etc >

Nanoparticulation of BCG-CWS for application to bladder cancer therapy

Files in This Item:
WoS_64966_Nakamura.pdf1.62 MBPDFView/Open
Please use this identifier to cite or link to this item:

Title: Nanoparticulation of BCG-CWS for application to bladder cancer therapy
Authors: Nakamura, Takashi Browse this author
Fukiage, Masafumi Browse this author
Higuchi, Megumi Browse this author
Nakaya, Akihiro Browse this author →KAKEN DB
Yano, Ikuya Browse this author →KAKEN DB
Miyazaki, Jun Browse this author →KAKEN DB
Nishiyama, Hiroyuki Browse this author →KAKEN DB
Akaza, Hideyuki Browse this author →KAKEN DB
Ito, Toshihiro Browse this author
Hosokawa, Hiroyuki Browse this author →KAKEN DB
Nakayama, Toshinori Browse this author →KAKEN DB
Harashima, Hideyoshi Browse this author →KAKEN DB
Keywords: Packaging
Delivery system
Bladder cancer
Cancer immunotherapy
Issue Date: 28-Feb-2014
Publisher: Elsevier science bv
Journal Title: Journal of controlled release
Volume: 176
Start Page: 44
End Page: 53
Publisher DOI: 10.1016/j.jconrel.2013.12.027
PMID: 24389133
Abstract: The Mycobacterium bovis Bacille Calmette-Guerin cell wall skeleton (BCG-CWS) could be used to replace live BCG as a bladder cancer drug. However, because BCG-CWS is poorly soluble, has a strong-negative charge, very high molecular weight and heterogeneity in size of tens of mu m, it cannot be used in such an application. We report herein on the development of a novel packaging method that permits BCG-CWS to be encapsulated into 166 nm-sized lipid particles. The BCG-CWS encapsulated nano particle (CWS-NP) has a high uniformity and can be easily dispersed. Thus, it has the potential for use as a packaging method that would advance the scope of applications of BCG-CWS as a bladder cancer drug. In a functional evaluation, CWS-NP was efficiently taken up by mouse bladder tumor (MBT-2) cells in vitro and inhibited tumor growth in mice bearing MBT-2 tumors. Moreover, intravesically administered CWS-NP showed significant antitumor effects in a rat model with naturally developed bladder cancer. An enhancement in Th1 differentiation by CWS-NP was also confirmed in human T cells. In conclusion, CWS-NP represents a promising delivery system for BCG-CWS for clinical development as a potent bladder cancer drug. (C) 2013 Elsevier B. V. All rights reserved.
Type: article (author version)
Appears in Collections:薬学研究院 (Faculty of Pharmaceutical Sciences) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Submitter: 中村 孝司

Export metadata:

OAI-PMH ( junii2 , jpcoar )

MathJax is now OFF:


 - Hokkaido University